Physician profile
Robert Thomas
NPI 1497991913
$60,464.17
in general payments reported to CMS, 2019-2025
21 companies · $3,778 in 2025
The $3,778 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,800 · 2022: $10K · 2023: $24K · 2024: $16K · 2025: $3,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Travel and Lodging: $10K · Consulting Fee: $7,490 · Food and Beverage: $7,234 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,785 · Education: $13.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,660.43 |
| Travel and Lodging | $10,290.29 |
| Consulting Fee | $7,490.00 |
| Food and Beverage | $7,233.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,785.00 |
| Education | $13.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $52,833.10 | 2021-2024 | Senza, Omnia, Nevro |
| Boston Scientific Corporation | $2,926.36 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Globus Medical, INC. | $2,442.99 | 2025 | Senza, Vyrsa V1 |
| Abbott Laboratories | $439.27 | 2021-2025 | Eterna, Proclaim |
| Spr Therapeutics, INC | $377.84 | 2024-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $255.35 | 2023-2025 | Belbuca |
| Axsome Therapeutics, INC. | $228.10 | 2025 | Auvelity |
| Mml US, INC. | $194.45 | 2025 | Reactiv8 |
| Vertos Medical, INC. | $187.17 | 2022-2024 | Mild Device Kit |
| Curonix LLC | $138.00 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Azurity Pharmaceuticals, INC. | $124.27 | 2023-2024 | Horizant, Horizant |
| Scilex Pharmaceuticals INC. | $55.92 | 2021-2025 | |
| Stimwave Technologies Incorporated | $52.41 | 2022 | |
| Pfizer INC. | $39.33 | 2025 | |
| Valinor Pharma, LLC | $38.66 | 2025 | Movantik |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $31.46 | 2023 | |
| Arbor Pharmaceuticals, INC. | $30.70 | 2021 | |
| Saluda Medical Americas, INC. | $25.16 | 2024 | Evoke |
| Nalu Medical, INC. | $15.31 | 2023 | Nalu Neurostimulation System |
| Biodelivery Sciences International, INC. | $15.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.